Experts Perspectives: Navigating Newly Diagnosed MM to Early Relapse - Episode 1

Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates

October 18, 2024

Ajay Chari, MD, Noopur S. Raje, MD, Adriana Rossi, MD, Weill Cornell Medical College, Natalie Callander, MD, Tom Martin, MD

Panelists discuss the findings of the PERSEUS trial and the recent cytogenetic risk analysis for patients with newly diagnosed transplant-eligible multiple myeloma. They then explore the CASSIOPEIA trial and its implications regarding daratumumab quadruplet induction regimens.

Now Viewing

EP. 1: Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates

EP. 2: Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

EP. 3: Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies

EP. 4: MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

EP. 5: Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma

EP. 6: Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

EP. 7: Considerations for Use of CAR T-cell Therapy in Multiple Myeloma

EP. 8: CAR T-cell Therapies for Multiple Myeloma: KarMMa-3 and CARTITUDE-4 Study Updates at IMS 2024

EP. 9: Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers

EP. 10: Importance of Early Referral for CAR T-cell Therapy in Multiple Myeloma and Patient Quality of Life

Let’s start with the topic of patients with newly diagnosed multiple myeloma who are transplant eligible. Can you please briefly review the PERSEUS trial and findings, as well as the recent cytogenetic risks analysis?
Continuing with daratumumab quadruplet induction regimens – Dr Raje: Can you tell us the CASSIOPEIA trial and findings?